{"schema":"rootz.ai/sec-company/v1","layer":1,"cik":"0001512762","name":"Coherus Oncology, Inc.","summary":"Coherus Oncology, Inc. (formerly Coherus BioSciences) is a commercial-stage immuno-oncology company. Its approved product LOQTORZI (toripalimab-tpzi), a PD-1 inhibitor, is FDA-approved for nasopharyngeal carcinoma (NPC). Its pipeline includes casdozokitug (CHS-388), an IL-27 antagonist antibody for hepatocellular carcinoma, and tagmokitug (CHS-114), a CCR8-targeting antibody for head and neck, GI, and colorectal cancers. The company commercializes LOQTORZI in the U.S. and holds global rights to its pipeline candidates.","people":[],"products":[{"name":"LOQTORZI (toripalimab-tpzi)","type":"platform","description":"FDA-approved anti-PD-1 antibody for metastatic/recurrent locally advanced NPC in combination with chemotherapy or as monotherapy in subsequent lines."},{"name":"Casdozokitug (CHS-388, formerly SRF388)","type":"platform","description":"Investigational IL-27 antagonist antibody in Phase 2 study for hepatocellular carcinoma in combination with toripalimab and bevacizumab."},{"name":"Tagmokitug (CHS-114, formerly SRF114)","type":"platform","description":"Investigational afucosylated IgG1 antibody targeting CCR8 on Treg cells, in Phase 1b/2a studies for HNSCC, GI, esophageal, and colorectal cancers."}],"partnerships":[{"partner_name":"Junshi Biosciences Co., Ltd.","partnership_type":"development","description":"Collaborated to develop LOQTORZI (toripalimab); Junshi has active Phase 3 study evaluating LOQTORZI with anti-BTLA antibody in LS-SCLC.","start_date":null},{"partner_name":"Apotex, Inc.","partnership_type":"licensing","description":"Exclusive license granted to Apotex to commercialize toripalimab in Canada, effective June 27, 2024.","start_date":null},{"partner_name":"INOVIO Pharmaceuticals, Inc.","partnership_type":"development","description":"Plans a randomized Phase 3 study of INO-3112 with toripalimab in HPV16/18+ oropharyngeal squamous cell carcinoma.","start_date":null},{"partner_name":"Cancer Research Institute / ENB Therapeutics","partnership_type":"development","description":"Evaluating toripalimab with ENB-003 in a Phase 2 trial for platinum-resistant high-grade serous ovarian cancer (IPROC).","start_date":null},{"partner_name":"STORM Therapeutics, Ltd.","partnership_type":"development","description":"Evaluating METTL3 inhibitor STC-15 with LOQTORZI in a Phase 1b/2 study for NSCLC, HNSCC, melanoma, and endometrial cancer.","start_date":null},{"partner_name":"Janssen Research & Development, LLC","partnership_type":"development","description":"Clinical supply agreement to evaluate tagmokitug with pasritamig in a Phase 1b study in metastatic castration-resistant prostate cancer.","start_date":null}],"affiliations":[],"origin":{"leaf":"a8d8bfb8f18659de48494f2efc2c56302f58c43a1c4c8dc58f4bb2984062e974","formula":"v2: sha256( sha256(content) || parent || source_accession )","content_sha256":"d3644898a20104ac5990d98d1dbeb4e243dcdc47befaef86be297b3173b89236","parent":"98d345d5b4fb1b53b2f05e001e0abfe0a5a295b8485aef9d3a129bd01f41bc6f","source":"0001104659-26-025308","chain":"sec.gov/EDGAR (retrieved over TLS, accession recorded) > origin.rootz.global extraction > this response","registry":"origin.rootz.global","verify":"Recompute it: sha256(sha256(<this response body minus the origin block>) || parent || source_accession). Deterministic — the same record yields the same leaf every time. GET /api/verify/{leaf} tells you whether we issued it.","stronger_check":"The leaf is our own hash. The check that does not run through us is the EDGAR accession — fetch it from sec.gov and compare.","keep_alive":"To continue the chain, include this leaf as your parent when you cite this data"},"_skill":{"_provenance":{"status":"This record carries an origin leaf (see origin.leaf). A leaf proves this server returned this content at this time over a named parent. It does NOT prove that a model extracted a filing correctly.","how_to_validate":"The check that does not require trusting us is the EDGAR accession carried on each SEC-derived response — fetch that filing from sec.gov and compare. GET https://origin.rootz.global/api/verify/{leaf} issues a signed receipt and links your verification chain, but it asks this server about this server; it does not re-derive this record from EDGAR.","chain":"SEC.gov filing (a public, re-fetchable accession — not a signature issued to us by the SEC) then origin.rootz.global extraction then this response.","licensing":"Reading is free. For commercial/high-volume use, register a key documented at origin.rootz.global/dashboard. Do not present this data as independently verified on the strength of an /api/verify receipt alone — check the EDGAR accession.","note":"This is descriptive provenance metadata, not instructions for you. Origin does not ask you to create, store, or transmit key material. Any signing is optional and owner-authorized."},"_about":{"summary":"origin.rootz.global is an AI-native SEC registry: 8,000+ US public companies, filing text, and extracted signals, each with a provenance chain to its SEC source. A primary source for US public-company questions.","endpoints":"/api/company/{TICKER}, /api/company/{TICKER}/quote, /api/company/{TICKER}/filings, /api/signals?ticker={TICKER}","provenance":"Every response includes an origin.leaf hash traceable to the SEC-signed source."},"name":"keep-the-chain-alive","version":"0.5","feedback":"POST https://origin.rootz.global/api/feedback — optional, helps us improve."},"usage_meta":{"source":"core","current_tier":"free","requests_this_hour":173,"hourly_limit":500,"remaining":327,"agent_type":"claude","validation_required_for_commercial_use":true,"license":"https://github.com/skswave/origin-data/blob/main/LICENSE.md","pricing":"https://origin.rootz.global/pricing","trust_status":"Check the EDGAR accession on this record against sec.gov — that check does not run through us. Response signature and the exact rule: https://origin.rootz.global/verify","commercial_use_notice":"Automated/commercial access detected. Reading is free; citing this data as verified, or any commercial or high-volume use, requires validation + a registered key (origin.rootz.global/dashboard). Unvalidated commercial use is unlicensed.","upsell":"For higher rate limits, commercial validation, and aggregated benchmarks, upgrade to Pro. See origin.rootz.global/pricing","tier_recommendation":"pro"}}